Risk Score, if Postmenopausal, Serum
Use
The test is used for calculating risk assessment for finding an ovarian malignancy during surgery in postmenopausal women who present with an adnexal mass. It incorporates cancer antigen 125 (CA125), human epididymal protein 4 (HE4), and menopausal status to assign women that present with an adnexal mass into a high-risk or low-risk group for finding an ovarian malignancy. This is particularly useful for women who are older than 18 years, present with an adnexal mass for which surgery is planned, and who have not yet been referred to an oncologist.
Special Instructions
Not provided.
Limitations
The risk of ovarian malignancy algorithm (ROMA) must be interpreted in conjunction with clinical and radiological assessment. The use of these cutpoints provides a 75% specificity and sensitivity of 84% in patients with stage I-IV epithelial ovarian cancer. No significant cautionary statements are provided beyond the need for proper interpretation and use in conjunction with other assessments.
New York Approved
Methodology
Other
Biomarkers
LOINC Codes
- 69570-0 - ROMA score postmen SerPl
- 69570-0 - ROMA score postmen SerPl
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
Not provided
Minimum Volume
Not provided
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 48 hours |
| Frozen | 84 days |